Insulet Co. (PODD) Receives Consensus Rating of “Buy” from Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have earned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $101.30.

Several research firms have recently weighed in on PODD. BidaskClub raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 19th. Oppenheimer set a $100.00 price target on shares of Insulet and gave the stock a “hold” rating in a research note on Tuesday, February 26th. Leerink Swann reissued an “outperform” rating and issued a $100.00 price target (down from $110.00) on shares of Insulet in a research note on Thursday, January 3rd. ValuEngine downgraded shares of Insulet from a “strong-buy” rating to a “buy” rating in a research note on Monday, January 7th. Finally, Northland Securities reissued a “buy” rating and issued a $100.00 price target on shares of Insulet in a research note on Tuesday, February 26th.

In other Insulet news, Director John A. Fallon sold 5,000 shares of Insulet stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP David Colleran sold 4,826 shares of Insulet stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $80.00, for a total transaction of $386,080.00. The disclosure for this sale can be found here. Insiders have sold 91,964 shares of company stock worth $8,526,720 over the last ninety days. 3.60% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of PODD. PRW Wealth Management LLC acquired a new stake in shares of Insulet during the fourth quarter valued at about $40,000. Cutler Group LP acquired a new stake in shares of Insulet during the fourth quarter valued at about $126,000. Nordea Investment Management AB acquired a new stake in shares of Insulet during the fourth quarter valued at about $159,000. Parallel Advisors LLC increased its position in shares of Insulet by 198.7% during the fourth quarter. Parallel Advisors LLC now owns 2,240 shares of the medical instruments supplier’s stock valued at $177,000 after acquiring an additional 1,490 shares during the last quarter. Finally, Stephens Inc. AR acquired a new stake in shares of Insulet during the fourth quarter valued at about $183,000.

PODD traded down $1.93 during midday trading on Monday, hitting $91.42. 39,181 shares of the company traded hands, compared to its average volume of 645,944. The company has a quick ratio of 3.37, a current ratio of 3.99 and a debt-to-equity ratio of 2.79. The company has a market cap of $5.57 billion, a price-to-earnings ratio of 1,828.40 and a beta of 1.59. Insulet has a 52-week low of $70.80 and a 52-week high of $108.90.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Monday, February 25th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.10. The firm had revenue of $164.90 million for the quarter, compared to the consensus estimate of $162.45 million. Insulet had a net margin of 0.58% and a return on equity of 1.73%. The company’s revenue for the quarter was up 26.4% on a year-over-year basis. During the same period last year, the firm posted ($0.12) earnings per share. On average, research analysts forecast that Insulet will post 0.23 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Featured Story: What is Net Asset Value (NAV)?

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.